Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
Oncotelic Therapeutics (OTCQB: OTLC) was featured in an editorial published Oct 30, 2025 highlighting advances in nanomedicine for oncology drug delivery.
The piece frames industry trends toward precision drug‑delivery systems that aim to improve bioavailability, tumor targeting and therapeutic index while limiting toxicity. It notes growing regulator interest in nanocarrier technologies and positions Oncotelic's proprietary Deciparticle™ platform as a technology intended to enhance the bioavailability and therapeutic index of existing cancer drugs and to improve performance of underutilized compounds.
Oncotelic Therapeutics (OTCQB: OTLC) è stata presentata in un editoriale pubblicato il 30 ottobre 2025 che evidenzia i progressi nanoscienza medica per la somministrazione di farmaci oncologici.
Il pezzo descrive le tendenze del settore verso sistemi di consegna mirata dei farmaci che mirano a migliorare la biodisponibilità, il targeting tumorale e l'indice terapeutico, al tempo che limitano la tossicità. Si segnala l'interesse crescente dei regolatori per le nanocarrier technologies e si posiziona la piattaforma proprietaria Deciparticle™ di Oncotelic come tecnologia finalizzata a migliorare la biodisponibilità e l'indice terapeutico dei farmaci antitumorali esistenti e a potenziare la performance di composti poco utilizzati.
Oncotelic Therapeutics (OTCQB: OTLC) fue presentado en un editorial publicado el 30 de octubre de 2025 que resalta los avances en nanomedicina para la administración de fármacos oncológicos.
El artículo describe las tendencias de la industria hacia sistemas de entrega de fármacos de precisión que buscan mejorar la biodisponibilidad, la focalización tumoral y el índice terapéutico, al tiempo que limitan la toxicidad. Señala el creciente interés de los reguladores en tecnologías de nanotransportadores y posiciona la plataforma propietaria Deciparticle™ de Oncotelic como una tecnología destinada a mejorar la biodisponibilidad y el índice terapéutico de fármacos contra el cáncer existentes y a mejorar el rendimiento de compuestos subutilizados.
Oncotelic Therapeutics (OTCQB: OTLC)는 2025년 10월 30일에 발표된 사설에서 암 치료 약물 전달을 위한 나노의학의 발전을 조명했습니다.
본 글은 바이오가용성, 종양 표적화 및 치료 지수를 개선하고 독성을 제한하기 위한 정밀 약물 전달 시스템으로의 산업적 추세를 설명합니다. 또한 규제 당국의 나노캐리어 기술에 대한 관심이 커지고 있으며 Oncotelic의 독점 플랫폼인 Deciparticle™가 기존 암 치료 약물의 생체이용률 및 치료 지수를 높이고 활용도가 낮은 화합물의 성능을 개선하는 기술로 자리매김한다고 밝힙니다.
Oncotelic Therapeutics (OTCQB: OTLC) a fait l'objet d'un éditorial publié le 30 octobre 2025 mettant en lumière les avancées nanomédecine pour la délivrance de médicaments anticancéreux.
Le texte présente les tendances de l'industrie vers des systèmes de délivrance de médicaments de précision visant à améliorer la biodisponibilité, la ciblage tumoral et l'indice thérapeutique tout en limitant la toxicité. Il note l'intérêt croissant des régulateurs pour les technologies nanocarrières et positionne la plateforme propriétaire Deciparticle™ d'Oncotelic comme une technologie conçue pour améliorer la biodisponibilité et l'indice thérapeutique des médicaments anticancéreux existants et pour améliorer les performances de composés sous-utilisés.
Oncotelic Therapeutics (OTCQB: OTLC) wurde in einem Editorial vom 30. Oktober 2025 vorgestellt, das Fortschritte in der Nanomedizin für die Verabreichung von Krebstherapeutika hervorhebt.
Der Beitrag skizziert Branchentrends hin zu präzisen Arzneimittelabgabesystemen, die Bioverfügbarkeit, Tumorzielgerichtetheit und den therapeutischen Index verbessern und gleichzeitig die Toxizität begrenzen. Es wird auf das wachsende regulatorische Interesse an Nanocarrier-Technologien hingewiesen und Oncotelics proprietäre Deciparticle™-Plattform als Technologie positioniert, die darauf abzielt, die Bioverfügbarkeit und den therapeutischen Index bestehender Krebsmedikamente zu erhöhen und die Leistung von unterutilisierten Verbindungen zu verbessern.
Oncotelic Therapeutics (OTCQB: OTLC) تم إدراجها في افتتاحية نشرت في 30 أكتوبر 2025 تبرز التطورات في النانوميديسين لتوصيل أدوية الأورام.
الإطار يعرض اتجاهات الصناعة نحو أنظمة توصيل أدوية دقيقة تهدف إلى تحسين التوافر الحيوي، واستهداف الورم، والفهرس العلاجي مع الحد من السمية. كما يلاحظ الاهتمام التنظيمي المتزايد بتقنيات الناقلات النانوية ويضع منصة Deciparticle™ المملوكة لـ Oncotelic ك تقنية تهدف إلى تعزيز التوافر الحيوي والفهرس العلاجي للأدوية السرطانية الموجودة وتحسين أداء المركبات غير المستغلة.
- None.
- None.
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability,” please visit: https://nnw.fm/37Awq
The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (FDA), along with other regulators for nanocarrier-based delivery technologies used in advanced therapeutics.
This accelerating adoption highlights a broader shift across the industry: a race to optimize how medicines are transported, absorbed, and activated within the human body. Oncotelic Therapeutics Inc. is at the forefront of this movement with its proprietary Deciparticle(TM) platform, designed to enhance both the bioavailability and therapeutic index of existing oncology drugs. By improving the performance of underutilized compounds, the technology could help redefine standards for cancer treatment.
About Oncotelic Therapeutics Inc.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns
For further information, please visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
FAQ
What did Oncotelic (OTLC) announce on October 30, 2025?
How does Oncotelic's Deciparticle™ platform aim to affect cancer drugs (OTLC)?
Does the Oct 30, 2025 editorial state any FDA approvals for Oncotelic (OTLC)?
Where was Oncotelic's (OTLC) editorial placement published on Oct 30, 2025?
Will Oncotelic's (OTLC) Deciparticle™ platform change current cancer‑therapy standards?
Does the Oct 30, 2025 release include clinical trial data or financial metrics for Oncotelic (OTLC)?
